Bharat Biotech begins clinical trials of Spanish TB vaccine , MTBVAC in India
MTBVAC , the Spanish tuberculosis vaccine , the first live attenuated vaccine of Mycobacterium tuberculosis isolated from a human , reaches a new milestone by starting clinical trials in India , the most populated country in the world and the one with the highest number of cases of this infectious disease . The trials are carried out by Bharat Biotech in close collaboration with Biofabri . Trials to evaluate the safety and immunogenicity of MTBVAC have started with a pivotal safety , immunogenicity and efficacy trial planned to start in 2025 .
After more than three decades of research , Esteban Rodriguez , CEO of Biofabri says : « It is a giant step to test in adults and adolescents in the country where 28 % of the world ’ s TB cases accumulate » and concludes that more effort and funding is needed to combat TB , which remains one of the world ’ s leading infectious causes of death , especially in India .
Zydus receives WHO ’ s approval for ‘ Usnoflast ’ as recommended name for ZYIL1
BioTech
Zydus , a leading discovery-based , global pharmaceutical company , has received approval from WHO International Non-proprietary Names ( INN ) for “ Usnoflast ” as the recommended name for ZYIL1 . The INN system aims to provide healthcare professionals with a unique and universal designated name for each pharmaceutical substance . Usnoflast ( ZYIL1 ) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus . Studies have demonstrated that ZYIL1 is highly potent in human whole blood assay and can suppress inflammation caused by the NLRP3 inflammasome . Usnoflast ( ZYIL1 ) has also received permission from USFDA , to initiate the Phase II clinical study in patients with Parkinson ’ s disease . It is estimated that there are more than 8.5 mn people in the world suffering from Parkinson ’ s disease , with 1 mn suffering from the disease in the USA .
BIOVOICENEWS . COM 09